Investors feel optimistic about Abbott's robust strength in the Core Diagnostics business. Yet, unfavorable forex impacts are concerning.

Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose ...

The FreeStyle Libre 3 system consists of the sensor around the size of a £1 coin that is worn on the upper arm and an app which can be used by users to record their real-time glucose levels and ...

Insulet announces the launch of Omnipod 5 in five more countries in Europe, Italy, Denmark, Finland, Norway and Sweden.

Corporation announced the Omnipod 5 Automated Insulin Delivery System is now commercially available in five more ...

For the full calendar of 2024, Abbott recorded sales of $41.95 billion, following the launches last year of a new heart valve ...

Abbott (NYSE:ABT) today highlighted significant growth within its Diabetes business amid its fourth-quarter results for 2024.

Going by the Zacks Consensus Estimate, the company’s earnings are likely to increase 17.1% in 2024 on ... compatible with Abbott’s FreeStyle Libre 2 Plus CGM sensor in the United States.

sensor-based continuous glucose monitoring (CGM) system, FreeStyle Libre. In the third quarter of 2024, in Diabetes Care, sales of CGM exceeded $1.6 billion and grew 21%. In August, the company ...

These are tech expert Marc Salzman's top CES picks for USA TODAY after his hands-on with future gadgets and gear in Las Vegas.

Kevin Sayer said at the J.P. Morgan Healthcare Conference that Dexcom also expects to release a 15-day glucose sensor in the ...